Sodium-glucose cotransporter 1 (SGLT1) inhibitors available for clinical use
An SGLT1 inhibitor that is available for clinical use is sotagliflozin, which is a dual inhibitor of SGLT1 and SGLT2.[1]
Approved SGLT1 inhibition agents
- Sotagliflozin (dual SGLT1/SGLT2 inhibitor; brand names include Inpefa and Zynquista): approved as an SGLT1/SGLT2 inhibitor for clinical use.[1][2]
SGLT1 selectivity scope
Sotagliflozin inhibits both intestinal SGLT1 and renal SGLT2 transporters.[1][2]
Clinical-use status by selectivity
No highly selective SGLT1-only inhibitor with widespread clinical use is identified in the available regulatory labeling sources reviewed here.[1][2]